Drug maker Lupin on Tuesday said it has received approval from the U.S. health regulator to market a generic medication to treat swelling and pain in the eye.
The company has received approval from the U.S. Food and Drug Administration for Bromfenac Ophthalmic Solution, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Sun Pharma's BromSite Ophthalmic Solution, it added.
Lupin is the exclusive first-to-file for this product, the drug maker said.
ADVERTISEMENT
Shares of Lupin ended 0.43% higher at Rs 1,579.75 apiece on the BSE.
ADVERTISEMENT
RECOMMENDED FOR YOU
Bain-Backed Indian Auto Parts Maker Is Said To Consider 2026 IPO
Jul 31, 2025
Dr Reddy's Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit
Jul 18, 2025
AstraZeneca Pharma Gets CDSCO Nod For Import, Sale Of Bladder Cancer Drug
Jul 14, 2025
Alembic Pharma Shares Surge After USFDA Nod For New Ovarian Cancer Drug
Jun 30, 2025
POPULAR
1
Pixel 10 Pro Fold Specifications Surface Online Ahead Of Aug. 20 Launch, Check Key Features
2
Mumbai Rains LIVE Updates: IMD Issues Red Alert; Schools, Colleges Closed; Airport Issues Passenger Advisory
3
Google Issues Warning As Hackers Mimic Gmail Security Alerts To Steal Passwords
4
iPhone 17 Pro Max Camera Upgrades Revealed In New Leaks: Here’s What We Know
5